VistaGen Therapeutics Q1 2025 Adj EPS $(0.35) Beats $(0.41) Estimate, Sales $84.00K Miss $300.00K Estimate
Author: Benzinga Newsdesk | August 13, 2024 04:23pm
VistaGen Therapeutics (NASDAQ:
VTGN) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.41) by 14.63 percent. The company reported quarterly sales of $84.00 thousand which missed the analyst consensus estimate of $300.00 thousand by 72.00 percent. This is a 52.70 percent decrease over sales of $177.60 thousand the same period last year.
Posted In: VTGN